| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromosome Aberrations | 10 | 2025 | 70 | 1.690 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 | 2018 | 47 | 1.680 |
Why?
|
| In Situ Hybridization, Fluorescence | 13 | 2025 | 161 | 1.040 |
Why?
|
| Hematologic Neoplasms | 2 | 2020 | 45 | 0.690 |
Why?
|
| Loss of Heterozygosity | 2 | 2018 | 25 | 0.600 |
Why?
|
| Genomics | 3 | 2026 | 386 | 0.590 |
Why?
|
| Genetic Testing | 1 | 2020 | 142 | 0.580 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 73 | 0.560 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2026 | 193 | 0.540 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 526 | 0.480 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 464 | 0.480 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2026 | 93 | 0.450 |
Why?
|
| Preimplantation Diagnosis | 2 | 2006 | 5 | 0.430 |
Why?
|
| Cytogenetic Analysis | 4 | 2025 | 26 | 0.420 |
Why?
|
| Translocation, Genetic | 2 | 2013 | 74 | 0.400 |
Why?
|
| Cytogenetics | 1 | 2013 | 9 | 0.390 |
Why?
|
| Leukemia, Lymphoid | 1 | 2013 | 10 | 0.390 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2013 | 5 | 0.390 |
Why?
|
| Interleukin-2 | 1 | 2013 | 167 | 0.380 |
Why?
|
| Amniotic Fluid | 1 | 2012 | 8 | 0.370 |
Why?
|
| Neoplasms | 2 | 2020 | 1372 | 0.360 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 40 | 0.360 |
Why?
|
| Oligonucleotides | 1 | 2013 | 229 | 0.340 |
Why?
|
| Trisomy | 2 | 2008 | 22 | 0.310 |
Why?
|
| Mutation | 5 | 2026 | 2666 | 0.310 |
Why?
|
| Paraproteinemias | 2 | 2009 | 16 | 0.310 |
Why?
|
| Eosinophilia | 2 | 2008 | 37 | 0.300 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1039 | 0.290 |
Why?
|
| Plasma Cells | 1 | 2009 | 52 | 0.280 |
Why?
|
| Interphase | 1 | 2009 | 68 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2008 | 33 | 0.280 |
Why?
|
| Repressor Proteins | 5 | 2024 | 351 | 0.270 |
Why?
|
| Dioxygenases | 2 | 2026 | 36 | 0.260 |
Why?
|
| DNA Probes | 1 | 2006 | 33 | 0.250 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2006 | 37 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-ets | 3 | 2017 | 19 | 0.240 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 50 | 0.240 |
Why?
|
| DNA-Binding Proteins | 4 | 2026 | 1225 | 0.230 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2026 | 65 | 0.230 |
Why?
|
| GTP Phosphohydrolases | 1 | 2026 | 64 | 0.230 |
Why?
|
| Humans | 32 | 2026 | 65498 | 0.230 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2013 | 7 | 0.170 |
Why?
|
| Bone Marrow Cells | 3 | 2013 | 237 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 2 | 2013 | 63 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2025 | 372 | 0.150 |
Why?
|
| Male | 16 | 2026 | 31208 | 0.150 |
Why?
|
| Mitoxantrone | 1 | 2018 | 16 | 0.140 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2011 | 67 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 44 | 0.140 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2017 | 2 | 0.140 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 37 | 0.130 |
Why?
|
| Rare Diseases | 1 | 2017 | 45 | 0.130 |
Why?
|
| Thyroid Gland | 1 | 2017 | 83 | 0.130 |
Why?
|
| DNA | 1 | 2002 | 852 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 87 | 0.130 |
Why?
|
| Pregnancy | 4 | 2012 | 2392 | 0.120 |
Why?
|
| Middle Aged | 10 | 2026 | 18393 | 0.120 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 21 | 0.120 |
Why?
|
| Female | 13 | 2026 | 34216 | 0.110 |
Why?
|
| Prognosis | 1 | 2020 | 1789 | 0.110 |
Why?
|
| Aged | 9 | 2026 | 15062 | 0.110 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2026 | 35 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 297 | 0.110 |
Why?
|
| Karyotyping | 4 | 2011 | 48 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2011 | 61 | 0.100 |
Why?
|
| Metaphase | 1 | 2013 | 36 | 0.100 |
Why?
|
| Mastocytosis, Systemic | 1 | 2013 | 5 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2026 | 344 | 0.100 |
Why?
|
| Mast Cells | 1 | 2013 | 51 | 0.090 |
Why?
|
| Amniocentesis | 1 | 2012 | 6 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 426 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2012 | 64 | 0.090 |
Why?
|
| CpG Islands | 1 | 2013 | 219 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2026 | 5650 | 0.090 |
Why?
|
| Fetus | 1 | 2012 | 103 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 70 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2026 | 314 | 0.090 |
Why?
|
| Adult | 9 | 2026 | 17467 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2011 | 14 | 0.090 |
Why?
|
| Myeloproliferative Disorders | 1 | 2011 | 15 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2012 | 195 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 210 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 196 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 501 | 0.080 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2009 | 6 | 0.070 |
Why?
|
| Basophils | 1 | 2009 | 15 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2009 | 6 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2009 | 33 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2009 | 24 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2026 | 300 | 0.070 |
Why?
|
| Gene Rearrangement | 3 | 2017 | 41 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2001 | 11 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 19 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 54 | 0.070 |
Why?
|
| Polyploidy | 1 | 2008 | 13 | 0.070 |
Why?
|
| Mosaicism | 1 | 2008 | 29 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2188 | 0.070 |
Why?
|
| Neutropenia | 1 | 2008 | 68 | 0.070 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2008 | 64 | 0.070 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2008 | 72 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2007 | 17 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 205 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 128 | 0.060 |
Why?
|
| Cytarabine | 1 | 2026 | 36 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 1172 | 0.060 |
Why?
|
| Immunophenotyping | 3 | 2011 | 194 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2006 | 176 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2007 | 513 | 0.060 |
Why?
|
| Chromosome Painting | 2 | 2001 | 6 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2008 | 1557 | 0.050 |
Why?
|
| Biopsy | 1 | 2006 | 460 | 0.050 |
Why?
|
| Chromosome Deletion | 2 | 2001 | 42 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 82 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2018 | 579 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2026 | 353 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 796 | 0.050 |
Why?
|
| Blastomeres | 1 | 2002 | 12 | 0.050 |
Why?
|
| Young Adult | 2 | 2026 | 4839 | 0.050 |
Why?
|
| Genetics, Medical | 1 | 2002 | 10 | 0.050 |
Why?
|
| Age Factors | 2 | 2018 | 1592 | 0.040 |
Why?
|
| DNA Primers | 1 | 2002 | 301 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 51 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2001 | 10 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 897 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 741 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2026 | 924 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 1224 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 149 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 79 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 2111 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2017 | 18 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 9 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2017 | 35 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 68 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 106 | 0.030 |
Why?
|
| Child | 1 | 2006 | 4623 | 0.030 |
Why?
|
| Karyotype | 1 | 2015 | 18 | 0.030 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 15 | 0.030 |
Why?
|
| Standard of Care | 1 | 2015 | 29 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 72 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 1995 | 151 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1995 | 296 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 173 | 0.020 |
Why?
|
| Adolescent | 2 | 2018 | 6333 | 0.020 |
Why?
|
| Abnormal Karyotype | 1 | 2013 | 2 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 1995 | 277 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 32 | 0.020 |
Why?
|
| Clone Cells | 1 | 2013 | 111 | 0.020 |
Why?
|
| Genes, abl | 1 | 2012 | 9 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 17 | 0.020 |
Why?
|
| PAX5 Transcription Factor | 1 | 2012 | 13 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 198 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 32 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 59 | 0.020 |
Why?
|
| Chromosome Banding | 2 | 2001 | 13 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2013 | 282 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 113 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 34 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 69 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 86 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1710 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 847 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2011 | 144 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 321 | 0.020 |
Why?
|
| Mice | 2 | 2012 | 11145 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2009 | 10 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 7 | 0.020 |
Why?
|
| Leukopenia | 1 | 2008 | 16 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 56 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 374 | 0.020 |
Why?
|
| Lymphoma, Follicular | 1 | 2008 | 18 | 0.020 |
Why?
|
| Granulocytes | 1 | 2008 | 73 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 5811 | 0.020 |
Why?
|
| Leukemia | 1 | 2008 | 62 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 193 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2008 | 133 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2008 | 237 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 663 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 2162 | 0.020 |
Why?
|
| Mitosis | 1 | 2008 | 222 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 643 | 0.010 |
Why?
|
| Monocytes | 1 | 2008 | 361 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2009 | 631 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3489 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 742 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 957 | 0.010 |
Why?
|
| Animals | 3 | 2012 | 21394 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 3156 | 0.010 |
Why?
|
| Lymphangioma, Cystic | 1 | 2001 | 2 | 0.010 |
Why?
|
| Chorionic Villi Sampling | 1 | 2001 | 2 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 2001 | 12 | 0.010 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2001 | 50 | 0.010 |
Why?
|
| United States | 1 | 2008 | 8149 | 0.010 |
Why?
|
| Fushi Tarazu Transcription Factors | 1 | 1995 | 4 | 0.010 |
Why?
|
| Steroidogenic Factor 1 | 1 | 1995 | 5 | 0.010 |
Why?
|
| Adrenal Insufficiency | 1 | 1995 | 10 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1995 | 97 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1995 | 173 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1995 | 171 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1995 | 687 | 0.010 |
Why?
|